
Opinion|Videos|October 24, 2024
Impact of Comorbidities on IPF Management
Author(s)Toby Maher, MD, PhD
Key Takeaways
- Comorbidities can obscure IPF symptoms, leading to diagnostic delays or misdiagnoses, complicating the clinical presentation.
- Comprehensive evaluation is crucial to tailor treatment plans addressing both IPF and comorbidities effectively.
Toby Maher, MD, PhD, discusses how comorbidities complicate the diagnosis and management of idiopathic pulmonary fibrosis (IPF) and influence treatment decisions, highlighting the need for a comprehensive approach in patient care.
Advertisement
Episodes in this series

Video content above is prompted by the following:
How do comorbidities affect diagnosis and management of IPF? In what ways do comorbidities affect treatment decisions?
Advertisement
Related to this article

Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.

Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.

Proinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.

An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.

Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.

Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5



